tiprankstipranks
Advertisement
Advertisement
Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)
PremiumThe FlyPlus Therapeutics reports Q1 EPS ($1.05), consensus (87c)
1M ago
Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split
Premium
Company Announcements
Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split
2M ago
Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement
Premium
The Fly
Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement
2M ago
Plus Therapeutics granted Orphan Drug Designation for Reyobiq
PremiumThe FlyPlus Therapeutics granted Orphan Drug Designation for Reyobiq
3M ago
Plus Therapeutics price target lowered to $12 from $37.50 at Maxim
Premium
The Fly
Plus Therapeutics price target lowered to $12 from $37.50 at Maxim
3M ago
Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code
Premium
The Fly
Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code
3M ago
Plus Therapeutics announces 1-for-25 reverse stock split
PremiumThe FlyPlus Therapeutics announces 1-for-25 reverse stock split
3M ago
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board
Premium
Company Announcements
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board
3M ago
Plus Therapeutics’ CNSide assay may reduce healthcare costs
Premium
The Fly
Plus Therapeutics’ CNSide assay may reduce healthcare costs
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100